Focused On-demand Library for Retinol dehydrogenase 11

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Androgen-regulated short-chain dehydrogenase/reductase 1; HCV core-binding protein HCBP12; Prostate short-chain dehydrogenase/reductase 1; Retinal reductase 1; Short chain dehydrogenase/reductase family 7C member 1

Alternative UPACC:

Q8TC12; A6NDK3; A8K062; B2RB26; B4DDW0; Q0QD40; Q6IAH5; Q9NRW0; Q9Y391


Retinol dehydrogenase 11 (RDH11) plays a pivotal role in the metabolism of retinoids, crucial for vision and cellular differentiation. Known by several names, including Androgen-regulated short-chain dehydrogenase/reductase 1 and Retinal reductase 1, RDH11 exhibits specificity for NADP and processes various forms of retinol. Its activity is essential for the conversion of retinol into retinal, a key intermediate in the visual cycle and in the biosynthesis of retinoic acid.

Therapeutic significance:

RDH11's involvement in Retinal dystrophy, juvenile cataracts, and short stature syndrome highlights its clinical significance. The disease's association with RDH11 mutations underscores the enzyme's role in ocular health and development. Understanding RDH11's function could lead to novel therapeutic strategies for managing retinal dystrophies and related disorders, offering hope for patients suffering from these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.